Actelion Pharmaceuticals Ltd Sustainability Profile
Actelion Pharmaceuticals Ltd., a leading biopharmaceutical company headquartered in Switzerland (CH), has established itself as a pioneer in the treatment of pulmonary arterial hypertension (PAH) and other serious conditions. Founded in 1997, Actelion has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which further solidified its market position. The company focuses on innovative therapies, particularly in the areas of cardiovascular and infectious diseases, with a portfolio that includes unique products like Tracleer and Opsumit. These therapies are distinguished by their targeted mechanisms and proven efficacy, addressing unmet medical needs. Actelion's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, recognised for its contributions to improving patient outcomes globally.
DitchCarbon Score
How does Actelion Pharmaceuticals Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Actelion Pharmaceuticals Ltd's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Actelion Pharmaceuticals Ltd, headquartered in Switzerland (CH), currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation. Actelion's climate initiatives are aligned with those of Johnson & Johnson, which has set ambitious targets for reducing carbon emissions across its operations. These initiatives include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Johnson & Johnson. However, specific reduction targets or achievements for Actelion itself have not been disclosed. As a subsidiary, Actelion is expected to contribute to the overarching sustainability goals of Johnson & Johnson, which include significant reductions in Scope 1, 2, and 3 emissions. The company is committed to advancing climate action, although detailed metrics and specific targets for Actelion have not been provided.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Actelion Pharmaceuticals Ltd's Industry?
How Carbon Intensive is Actelion Pharmaceuticals Ltd's Location?
Actelion Pharmaceuticals Ltd's Scope 3 Categories Breakdown
Actelion Pharmaceuticals Ltd's Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Actelion Pharmaceuticals Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Actelion Pharmaceuticals Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
